Literature DB >> 1813908

Should bupropion dosage be adjusted based upon therapeutic drug monitoring?

S H Preskorn1.   

Abstract

Bupropion is the next antidepressant which should be studied aggressively to test the value of therapeutic drug monitoring (TDM). This paper will present the basis for this conclusion.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1813908

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


  4 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report.

Authors:  Mei-Ling Chen; Vinod P Shah; Derek Ganes; Kamal K Midha; James Caro; Prabu Nambiar; Mario L Rocci; Avinash G Thombre; Bertil Abrahamsson; Dale Conner; Barbara Davit; Paul Fackler; Colm Farrell; Suneel Gupta; Russell Katz; Mehul Mehta; Sheldon H Preskorn; Gerard Sanderink; Salomon Stavchansky; Robert Temple; Yaning Wang; Helen Winkle; Lawrence Yu
Journal:  AAPS J       Date:  2010-05-04       Impact factor: 4.009

Review 3.  Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Authors:  Mazda Adli; Christopher Baethge; Andreas Heinz; Nicolas Langlitz; Michael Bauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-29       Impact factor: 5.760

4.  Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.

Authors:  Peter H Silverstone; Robert Williams; Louis McMahon; Rosanna Fleming; Siobhan Fogarty
Journal:  Ann Gen Psychiatry       Date:  2008-12-23       Impact factor: 3.455
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.